Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

Francis Baumgartner, Constance Baer, Stefanos Bamopoulos, Edward Ayoub, Marietta Truger, Manja Meggendorfer, Miriam Lenk, Gregor Hoermann, Stephan Hutter, Heiko Müller, Wencke Walter, Martha-Lena Müller, Niroshan Nadarajah, Piers Blombery, Ulrich Keller, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach

Blood (2024) 143 (12): 1139–1156.

https://doi.org/10.1182/blood.2023021199

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Blood (2024) 143 (8): 673–684.

https://doi.org/10.1182/blood.2023021306

Published: 2024

Includes: Supplemental data

Journal Articles

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

Rithin Nedumannil, Tal Karmi, Piers Blombery, Charlotte Hughes, Jeff Szer, David S. Ritchie, Lynette C.Y. Chee

Blood (2023) 142 (Supplement 1): 629.

https://doi.org/10.1182/blood-2023-174666

Published: 2023

Journal Articles

Australasian Leukaemia & Lymphoma Group NHL35-Pacific: An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma - Trial in Progress

Katharine L. Lewis, Piers Blombery, Nagendra Prasad Sungala, Chun Kei Kris Ma, Pratyush Giri, Vinay Vanguru, Tara Cochrane, Joanna Katarzyna Czerwinski, Denise Lee, Nada Hamad, Roslyn Francis, Mannu Walia, Julia Carlson, Belinda E Butcher, Chan Y. Cheah

Blood (2023) 142 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2023-185160

Published: 2023

Journal Articles

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 6939.

https://doi.org/10.1182/blood-2023-178806

Published: 2023

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

Clinical Utility of Circulating Tumor (ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma

Imogen Caldwell, Yan Zhuang Yap, Mark R Dowling, Javad Saghebi, Aaron Jun Ning Wong, Roxane Legaie, Rainier Arnolda, Clarissa Wilson, Danielle Ignacio, Nicole O'Leary, Stephanie Yaung, Bowdoin Su, Corinna Woestmann, Michael Dickinson, Ella Thompson, Piers Blombery

Blood (2023) 142 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2023-182999

Published: 2023

Journal Articles

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Ing Soo Tiong, Tamia Nguyen, Charis Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E Lew, Fiona C. Brown, Donia Moujalled, Christine Muttiah, Daniel Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah-Jane Dawson, Andrew H. Wei, Geoffrey Lindeman, Piers Blombery

Blood (2023) 142 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2023-180386

Published: 2023

Journal Articles

Evaluating Multidisciplinary Bone Marrow Failure Care (EMBRACE) - a Hybrid Implementation-Effectiveness Study

Lucy C. Fox, Nicole Den Elzen, Laura Barth, Kelsey Man, Paul James, Jillian Francis, Lin Cheng, Karin A Thursky, Ashish Bajel, David S. Ritchie, Piers Blombery

Blood (2023) 142 (Supplement 1): 369.

https://doi.org/10.1182/blood-2023-177593

Published: 2023

Journal Articles

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Blood (2023) 141 (7): 800–805.

https://doi.org/10.1182/blood.2022017874

Published: 2023

Includes: Supplemental data

Journal Articles

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Blood (2023) 141 (6): 634–644.

https://doi.org/10.1182/blood.2022016090

Published: 2023

Includes: Supplemental data

Journal Articles

Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes

Blood (2023) 141 (6): 645–658.

https://doi.org/10.1182/blood.2022016783

Published: 2023

Includes: Supplemental data

Journal Articles

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 141 (5): 534–549.

https://doi.org/10.1182/blood.2022018221

Published: 2023

Includes: Supplemental data

Journal Articles

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Blood (2022) 140 (20): 2127–2141.

https://doi.org/10.1182/blood.2022016040

Published: 2022

Includes: Supplemental data

Journal Articles

Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing

Piers Blombery, Wencke Walter, Stephan Hutter, Constance Baer, Maki Sakuma, Heiko Mueller, Simon Wu, Imogen R Caldwell, Wolfgang Kern, Manja Meggendorfer, Claudia Haferlach, Torsten Haferlach

Blood (2022) 140 (Supplement 1): 3546–3547.

https://doi.org/10.1182/blood-2022-163300

Published: 2022

Journal Articles

Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy

Anna Maierhofer, Lucy C Fox, Stephan Hutter, Constance Baer, Ella Thompson, Tamia Nguyen, Nicole Den Elzen, Robin J Filshie, Ing S Tiong, Niroshan Nadarajah, Manja Meggendorfer, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Piers Blombery

Blood (2022) 140 (Supplement 1): 8676–8677.

https://doi.org/10.1182/blood-2022-163064

Published: 2022

Journal Articles

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David A Westerman, Stephen Lade, David Ritchie, Rachel M Koldej, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen R Caldwell, Georgina L Ryland, Jing Xie, Huw Morgan, Michael Dickinson

Blood (2022) 140 (Supplement 1): 181–183.

https://doi.org/10.1182/blood-2022-160459

Published: 2022

Journal Articles

Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1 , GATA2 and DDX41

Anna L. Brown, Claire Homan, Michael W. Drazer, Kai Yu, David Lawrence, Jinghua Feng, Luis Arriola-Martinez, Matthew Pozsgai, Kelsey McNeely, Thuong Ha, Parvathy Venugopal, Peer Arts, Sarah King-Smith, Jesse JC Cheah, Mark Armstrong, Csaba Bödör, Paul Wang, Alan B. Cantor, Mario Cazzola, Erin Degelman, Courtney D. DiNardo, Nicolas Duployez, Remi Favier, Stefan Fröhling, Ana Rio-Machin, Jeffery M. Klco, Alwin Krämer, Mineo Kurokawa, Joanne Lee, Luca Malcovati, Neil V Morgan, Georges Natsoulis, Carolyn Owen, Keyur P. Patel, Claude Preudhomme, Hana Raslova, Hugh Young Rienhoff, Jr., Tim Ripperger, Rachael Schulte, Kiran Tawana, Elvira Deolinda Rodrigues Pereira Velloso, Benedict Yan, Raman Sood, Amy Hsu, Steven M. Holland, Kerry Phillips, Nicola Poplawski, Milena Babic, Erika M Kwon Kim, Andrew H. Wei, Cecily Forsyth, Helen Mar Fan, Ian D Lewis, Julian Cooney, Rachel Susman, Lucy C Fox, Piers Blombery, Deepak Singhal, Devendra Hiwase, Andreas W Schreiber, Christopher N Hahn, Hamish S Scott, Paul P. Liu, Lucy A. Godley

Blood (2022) 140 (Supplement 1): 4030–4033.

https://doi.org/10.1182/blood-2022-167600

Published: 2022

Journal Articles

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Blood (2022) 140 (Supplement 1): 3341–3343.

https://doi.org/10.1182/blood-2022-167837

Published: 2022

Journal Articles

Dissecting the Knowns for the Unknowns: Refining the Classification of Genomic Variations in Hematological Diseases By the Clingen Hematological Cancer Taskforce (HCT)

Blood (2022) 140 (Supplement 1): 11810–11811.

https://doi.org/10.1182/blood-2022-170989

Published: 2022

NARROW

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Sensitive Molecular Detection of JAK2 V617F Is a Predictive Marker of Relapse in Patients with Myelofibrosis after Allogeneic Stem Cell Transplantation

Australasian Leukaemia & Lymphoma Group NHL35-Pacific: An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma - Trial in Progress

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Clinical Utility of Circulating Tumor (ct)DNA Quantity and Kinetics in Patients Undergoing CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Evaluating Multidisciplinary Bone Marrow Failure Care (EMBRACE) - a Hybrid Implementation-Effectiveness Study

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing

Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1 , GATA2 and DDX41

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Dissecting the Knowns for the Unknowns: Refining the Classification of Genomic Variations in Hematological Diseases By the Clingen Hematological Cancer Taskforce (HCT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only